Related Experiment Videos
Melatonin in osteosarcoma: an effective drug?
1Department of Physiology, University of Pretoria, South Africa.
Abstract:
The pineal indole amine melatonin has been shown to have oncostatic properties in a wide variety of neoplasms. Melatonin levels start to diminish before the onset of puberty and continue to decline during puberty. There appears to be a relationship between the rate of bone growth and the incidence of osteosarcoma (which was found to be highest in the long bones of the leg in the 10-14-year age group). It is hypothesized that the simultaneous decrease in melatonin levels (with diminishing oncostatic protection), concurrent with the exponential increase in bone growth during puberty (i.e. increased rate of cell proliferation), could be a factor in the typical age distribution of osteosarcoma. Melatonin is of value in combined chemotherapy, because it is non-toxic and can augment the anti-cancer action and decrease the side-effects of many other chemotherapeutic drugs. It is hoped that melatonin, as an adjunct to the routine chemotherapy of osteosarcoma, will help to improve the prognosis of this too often fatal disease.
Insights
Melatonin, a pineal hormone, may protect against osteosarcoma. Declining melatonin during puberty may coincide with increased bone cancer risk in adolescents.
Area of Science:
- Endocrinology
- Oncology
- Pediatric Medicine
Background:
- Melatonin, a pineal indole amine, exhibits oncostatic properties against various neoplasms.
- Melatonin levels naturally decrease during puberty, coinciding with increased bone growth and osteosarcoma incidence.
- Osteosarcoma typically affects the long bones of the leg in the 10-14-year age group.
Purpose of the Study:
- To investigate the potential role of decreasing melatonin levels during puberty in the age-related incidence of osteosarcoma.
- To explore melatonin's potential as an adjunct therapy in osteosarcoma treatment.
Main Methods:
- Observational analysis of melatonin levels and osteosarcoma incidence during puberty.
- Review of melatonin's pharmacological properties in cancer treatment.
Main Results:
- A hypothesized link exists between declining melatonin and increased osteosarcoma risk during puberty.
- Melatonin is non-toxic and can enhance chemotherapy efficacy while reducing side effects.
Conclusions:
- The decline in melatonin during puberty may contribute to the characteristic age distribution of osteosarcoma.
- Melatonin shows promise as an adjuvant therapy to improve osteosarcoma treatment outcomes.